PCK2 and nasopharyngeal carcinoma: More notably, we verified the effects of PCK2-pACSL4(T679) in in vivo tumor models and clarified its clinical relevance in nasopharyngeal carcinoma (NPC) chemotherapy and radiotherapy cohorts.